200 Participants Needed

PrEP Navigation for HIV Prevention

(T'Cher Trial)

NB
EM
Overseen ByErin Meek, DrPH
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: CrescentCare
Must be taking: PrEP
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators to get a clear answer.

What data supports the effectiveness of the treatment Peer PrEP Navigation for HIV Prevention?

Research shows that PrEP navigation services, which help people access and stick to their HIV prevention medication, can reduce the time it takes for patients to pick up their medication and increase overall PrEP use. These services are effective because they address barriers like lack of health insurance and provide personalized support, making it easier for people to start and continue using PrEP.12345

Is PrEP Navigation for HIV Prevention safe for humans?

The research does not provide specific safety data for PrEP Navigation services, but these services are designed to help people take their HIV prevention medication more effectively, which is generally considered safe.15678

How is the Peer PrEP Navigation treatment different from other HIV prevention treatments?

Peer PrEP Navigation is unique because it involves trained peers who help individuals access and adhere to HIV prevention services, like PrEP (pre-exposure prophylaxis), by providing education, support, and guidance through the healthcare system. This approach is particularly effective for minority groups who may face barriers to accessing traditional healthcare services.357910

What is the purpose of this trial?

The goal of this to address barriers and facilitators to PrEP uptake, and encourage adherence among trans women via a single arm stepped wedge clinical trial. The main question is to compare PrEP uptake and adherence outcomes among trans women in the T'Cher intervention to the delayed study arm.

Eligibility Criteria

This trial is for trans women over 18 living in the New Orleans area who want to start or restart PrEP, a medication that prevents HIV. Participants must not be infected with HIV, agree to study procedures, and attend quarterly visits. They cannot join if they're in another PrEP study or have conditions affecting consent or safety.

Inclusion Criteria

I was designated male at birth.
Live in the New Orleans metropolitan statistical area (which includes 8 parishes)
Provision of signed and dated informed consent form
See 4 more

Exclusion Criteria

Confirmed HIV infection by rapid algorithm testing and/or laboratory testing (described above)
Prior or current participation in the active arm of an HIV vaccine trial with evidence of vaccine-induced seropositivity
Concurrent or planned enrollment in a research study that provides PrEP
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive culturally informed health care empowerment and PrEP peer navigation and support through social determinant of health stressors

24 months

Follow-up

Participants are monitored for PrEP uptake and adherence, as well as changes in health care empowerment and social determinant stressors

4 weeks

Treatment Details

Interventions

  • Peer PrEP Navigation
Trial Overview The trial tests a Peer PrEP Navigation program aimed at increasing uptake and adherence to PrEP among trans women. It's a single arm stepped wedge design comparing outcomes of participants receiving the intervention immediately versus those with delayed access.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: PrEP peer navigationExperimental Treatment1 Intervention
Culturally informed health care empowerment and PrEP peer navigation and support through social determinant of health stressors

Find a Clinic Near You

Who Is Running the Clinical Trial?

CrescentCare

Lead Sponsor

Trials
1
Recruited
200+

Findings from Research

Nearly half of the participants (47%) who started pre-exposure prophylaxis (PrEP) for HIV prevention discontinued its use, primarily due to systemic issues such as financial problems and logistical barriers related to clinics and pharmacies.
Behavioral factors and concerns about medication side effects also contributed to discontinuation, highlighting the need for addressing both systemic and personal factors to improve PrEP retention and engagement in care.
Reasons for PrEP Discontinuation After Navigation at Sexual Health Clinics: Interactions Among Systemic Barriers, Behavioral Relevance, and Medication Concerns.Unger, ZD., Golub, SA., Borges, C., et al.[2023]
The PrIDE project, which ran from 2016 to 2019, successfully implemented a hybrid model of PrEP navigation that combined patient, peer, and systems navigation, leading to effective linking of clients to PrEP and social services across 12 health departments.
Having all PrEP services located in one place significantly boosted PrEP uptake, while challenges such as staff turnover and lack of health insurance were identified, with payment assistance shown to enhance client PrEP use in areas with insurance issues.
Informing the future of PrEP navigation: Findings from a five-site cluster evaluation.Salabarría-Peña, Y., Douglas, C., Brantley, M., et al.[2022]
Patient navigation is essential for linking individuals to HIV pre-exposure prophylaxis (PrEP) and re-engaging them in HIV care, as highlighted by a study involving 20 agency staff interviews and 300 patient surveys in Chicago.
Key navigation activities included screening for social determinants of health and providing guidance and referrals, although barriers such as limited staff and clinic capacity were noted, emphasizing the need for adequate resources to support these services.
Implementation and evaluation of patient navigation in Chicago: Insights on addressing the social determinants of health and integrating HIV prevention and care services.Greene, GJ., Reidy, E., Felt, D., et al.[2022]

References

Reasons for PrEP Discontinuation After Navigation at Sexual Health Clinics: Interactions Among Systemic Barriers, Behavioral Relevance, and Medication Concerns. [2023]
Informing the future of PrEP navigation: Findings from a five-site cluster evaluation. [2022]
Implementation and evaluation of patient navigation in Chicago: Insights on addressing the social determinants of health and integrating HIV prevention and care services. [2022]
Lessons Learned from an HIV Pre-Exposure Prophylaxis Coordination Program in San Francisco Primary Care Clinics. [2023]
Integrated Pharmacy and PrEP Navigation Services to Support PrEP Uptake: A Quality Improvement Project. [2020]
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. [2023]
What's PrEP?: peer navigator acceptability among minority MSM in Washington. [2022]
Adherence to Pre-exposure Prophylaxis in Black Men Who Have Sex with Men and Transgender Women in a Community Setting in Harlem, NY. [2022]
Perceptions of Sexual Risk, PrEP Services, and Peer Navigation Support among HIV-Negative Latinx and Black Men who have Sex with Men (MSM) Residing in Western Washington. [2023]
'PrEP'ing Memphis: A qualitative process evaluation of peer navigation support. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security